168 related articles for article (PubMed ID: 38189941)
1. [New psychoactive substances in emergency medicine].
Marinowitz R; Strube J; Schaper A
Nervenarzt; 2024 Jan; 95(1):28-34. PubMed ID: 38189941
[TBL] [Abstract][Full Text] [Related]
2. "Legal Highs"--An Emerging Epidemic of Novel Psychoactive Substances.
Zawilska JB
Int Rev Neurobiol; 2015; 120():273-300. PubMed ID: 26070762
[TBL] [Abstract][Full Text] [Related]
3. The Growing Problem of New Psychoactive Substances (NPS).
Madras BK
Curr Top Behav Neurosci; 2017; 32():1-18. PubMed ID: 27571747
[TBL] [Abstract][Full Text] [Related]
4. [Bonzai, lead and bath salt-poisoning with new and old drugs : Synthetic amphetamines, cathinones, cannabinoids and opioids-an overview].
Strube J; Schaper A
Med Klin Intensivmed Notfmed; 2019 Nov; 114(8):684-692. PubMed ID: 29404633
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
Gray R; Bressington D; Hughes E; Ivanecka A
J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
[TBL] [Abstract][Full Text] [Related]
6. New Psychoactive Substances (NPS) - a Challenge for the Addiction Treatment Services.
Scherbaum N; Schifano F; Bonnet U
Pharmacopsychiatry; 2017 May; 50(3):116-122. PubMed ID: 28444659
[TBL] [Abstract][Full Text] [Related]
7. New and Emerging Illicit Psychoactive Substances.
Graddy R; Buresh ME; Rastegar DA
Med Clin North Am; 2018 Jul; 102(4):697-714. PubMed ID: 29933824
[TBL] [Abstract][Full Text] [Related]
8. Examination of Synthetic Cannabinoid and Cathinone Use among a Drug-Using Offender Sample, 2013-2015.
Smith KE; Bunting AM; Staton M; Walker R; Shalash S; Winston E; Pangburn K
J Psychoactive Drugs; 2017; 49(5):436-445. PubMed ID: 28813207
[TBL] [Abstract][Full Text] [Related]
9. [New psychoactive substances and their prevalence in the Czech Republic].
Mravčík V; Běláčková V; Grohmannová K; Zábranský T
Cas Lek Cesk; 2015; 154(5):216-21. PubMed ID: 26612328
[TBL] [Abstract][Full Text] [Related]
10. Negative consequences of novel psychoactive substances use among the Polish users.
Wieczorek Ł; Bujalski M; Dąbrowska K
Psychiatr Pol; 2021 Apr; 55(2):447-469. PubMed ID: 34365491
[TBL] [Abstract][Full Text] [Related]
11. Motivations for new psychoactive substance use among regular psychostimulant users in Australia.
Sutherland R; Bruno R; Peacock A; Lenton S; Matthews A; Salom C; Dietze P; Butler K; Burns L; Barratt MJ
Int J Drug Policy; 2017 May; 43():23-32. PubMed ID: 28161577
[TBL] [Abstract][Full Text] [Related]
12. Phantom menace: novel psychoactive substances and the UK Armed Forces.
Hunter AH; Ayres T; Moreland N; Cox A
J R Army Med Corps; 2018 Nov; 164(6):450-457. PubMed ID: 29934414
[TBL] [Abstract][Full Text] [Related]
13. Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review.
Logan BK; Mohr ALA; Friscia M; Krotulski AJ; Papsun DM; Kacinko SL; Ropero-Miller JD; Huestis MA
J Anal Toxicol; 2017 Sep; 41(7):573-610. PubMed ID: 28459969
[TBL] [Abstract][Full Text] [Related]
14. Death cases involving certain new psychoactive substances: A review of the literature.
Kraemer M; Boehmer A; Madea B; Maas A
Forensic Sci Int; 2019 May; 298():186-267. PubMed ID: 30925344
[TBL] [Abstract][Full Text] [Related]
15. A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia.
Anderson C; Morrell C; Marchevsky D
BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25948854
[TBL] [Abstract][Full Text] [Related]
16. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature.
Chiappini S; Mosca A; Miuli A; Santovito MC; Orsolini L; Corkery JM; Guirguis A; Pettorruso M; Martinotti G; Di Giannantonio M; Schifano F
Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34204131
[No Abstract] [Full Text] [Related]
17. New/emerging psychoactive substances and associated psychopathological consequences.
Schifano F; Napoletano F; Chiappini S; Guirguis A; Corkery JM; Bonaccorso S; Ricciardi A; Scherbaum N; Vento A
Psychol Med; 2021 Jan; 51(1):30-42. PubMed ID: 31327332
[TBL] [Abstract][Full Text] [Related]
18. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.
Liechti M
Swiss Med Wkly; 2015; 145():w14043. PubMed ID: 25588018
[TBL] [Abstract][Full Text] [Related]
19. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
Grafinger KE; Bernhard W; Weinmann W
Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
[TBL] [Abstract][Full Text] [Related]
20. "Legal highs" - new players in the old drama.
Zawilska JB
Curr Drug Abuse Rev; 2011 Jun; 4(2):122-30. PubMed ID: 21711229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
